NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.
GBD. Risk Factors Collaborators (2020) Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2019;396(10258):1223–49.
Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98–105.
Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90.
Article CAS PubMed Google Scholar
Clozel M. Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol. 2022;100(7):573–83.
Article CAS PubMed Google Scholar
Burnier M. Update on endothelin receptor antagonists in hypertension. Curr Hypertens Rep. 2018;20(6):51.
US FDA. Corrected New Drug Application approval: aprocitentan. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217686Orig1s000Correctedltr.pdf. Accessed 10 Apr 2024.
Idorsia Pharmaceuticals US Inc. TRYVIOTM (aprocitentan): US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf. Accessed 22 Mar 2024.
Actelion Pharmaceuticals. Actelion provides an update on the progress towards launching Idorsia - key results for pipeline assets to be developed by Idorsia [media release]. 22 May 2017. https://www.globenewswire.com/en/news-release/2017/05/22/994421/0/en/Actelion-provides-an-update-on-the-progress-towards-launching-Idorsia-Key-results-for-pipeline-assets-to-be-developed-by-Idorsia.html.
Idorsia Pharmaceuticals. Idorsia announces collaboration with Janssen Biotech on aprocitentan [media release]. 4 Dec 2017. https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=1381336.
Idorsia Pharmaceuticals. Idorsia reacquires the world-wide rights to aprocitentan [media release]. 6 Sep 2023. https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3073952.
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736–45.
Article CAS PubMed Google Scholar
Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368(3):462–73.
Article CAS PubMed Google Scholar
Sidharta PN, Brussee JM, Schultz A, et al. The clinical evaluation of QTc interval prolongation for the dual endothelin receptor antagonist aprocitentan in a thorough QT/QTc study [abstract no. 024]. Clin Pharmacol Drug Dev. 2022;11(Suppl 1):66–7.
Sidharta PN, Melchior M, Kankam MK, et al. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Devel Ther. 2019;13:949–64.
Article CAS PubMed PubMed Central Google Scholar
Sidharta PN, Fischer H, Dingemanse J. Absorption, distribution, metabolism, and excretion of aprocitentan, a dual endothelin receptor antagonist, in humans. Curr Drug Metab. 2021;22(5):399–410.
Article CAS PubMed Google Scholar
Fontes MSC, Dingemanse J, Sidharta PN. Multiple-dose pharmacokinetics, safety, and tolerability of aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev. 2021;10(7):718–25.
Article CAS PubMed Google Scholar
Fontes MSC, Dingemanse J, Halabi A, et al. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep. 2022;12(1):19067.
Article CAS PubMed PubMed Central Google Scholar
Angeli F, Verdecchia P, Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Cardiol Ther. 2021;10(2):397–406.
Article PubMed PubMed Central Google Scholar
Sidharta PN, Dingemanse J. Effect of multiple-dose aprocitentan administration on the pharmacokinetics of midazolam in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45(2):227–34.
Article CAS PubMed Google Scholar
Sidharta PN, Dingemanse J. Effects of multiple-dose administration of aprocitentan on the pharmacokinetics of rosuvastatin. Clin Pharmacol Drug Dev. 2020;9(8):995–1002.
Article CAS PubMed Google Scholar
Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927–37.
Article CAS PubMed Google Scholar
Danaietash P, Verweij P, Wang JG, et al. Identifying and treating resistant hypertension in PRECISION: a randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022;24(7):804–13.
Article CAS PubMed Google Scholar
Schlaich M, Weber M, Bakris G, et al. Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension. Results from the PRECISION study [abstract]. J Hypertens. 2023;41(Suppl 3):e71.
Weber MA, Wang J, Flack JM, et al. Percentage of patients achieving blood pressure goals with aprocitentan, a dual endothelin receptor antagonist: results from a randomized, controlled phase 3 study (PRECISION) [abstract no. 13836]. Circulation. 2023;148(Suppl 1):A13836.
Bakris GL, Flack JM, Narkiewicz K, et al. Effects of aprocitentan for blood pressure lowering and proteinuria in patients with CKD and resistant hypertension [abstract no. FR-OR96]. J Am Soc Nephrol. 2023;34:56.
Flack JM, Schlaich M, Weber M, et al. Effects of aprocitentan, a dual endothelin receptor antagonist, on blood pressure in Black/African American patients with resistant hypertension: results from a randomized, controlled study (PRECISION) including a withdrawal phase [abstract no. 118]. Hypertension. 2023;80(Suppl 1):A118.
Verweij P, Danaietash P, Flamion B, et al. Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension. 2020;75(4):956–65.
留言 (0)